Stock Market & Financial Investment News

News Breaks January 10, 2012 13:59 EDT ACHN theflyonthewall.com: Achillion price target raised to $20 from $9 at Brean Murray Brean Murray said ACH-1625 had a high EVR rate, excellent resistance profile, and genotype 3 activity that makes this protease inhibitor significantly differentiated. The firm rates Achillion a Buy. :theflyonthewall.com News For ACHN From The Last 14 Days Check below for free stories on ACHN the last two weeks. There are 7 items on the Fly with pertinent information. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2012 07:01 EDT ACHN theflyonthewall.com: Achillion announces additional proof-of-concept data with ACH-2684 for HepC Subscribe for More Information :theflyonthewall.com May 15, 2012 09:00 EDT ACHN theflyonthewall.com: Achillion rises 7.4% Subscribe for More Information :theflyonthewall.com 08:59 EDT ACHN theflyonthewall.com: Achillion gaps up after ACH-3102 fast-tracked, resistance at $7.63, $8.09 Subscribe for More Information :theflyonthewall.com 07:16 EDT ACHN theflyonthewall.com: Achillion's ACH-3102 receives fast track designation From FDA Subscribe for More Information :theflyonthewall.com May 10, 2012 08:42 EDT ACHN theflyonthewall.com: Achillion shares at good entry point, says RW Baird Subscribe for More Information :theflyonthewall.com May 9, 2012 16:18 EDT ACHN theflyonthewall.com: Achillion reports Q1 EPS (13c), consensus (15c) Subscribe for More Information :theflyonthewall.com 07:15 EDT ACHN theflyonthewall.com: Achillion advances 2nd generation pan-genotypic NS5A inhibitor into clinicals Subscribe for More Information :theflyonthewall.com